<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00629226</url>
  </required_header>
  <id_info>
    <org_study_id>080071, CDR0000588196</org_study_id>
    <secondary_id>NCI-08-C-0071</secondary_id>
    <secondary_id>CCR 7205</secondary_id>
    <secondary_id>NCI-7893</secondary_id>
    <nct_id>NCT00629226</nct_id>
  </id_info>
  <brief_title>Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck Cancer</brief_title>
  <official_title>Phase I Study of Bortezomib and Cetuximab Without or With Cisplatin in Combination With Radiation Therapy for Advanced Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. Monoclonal antibodies, such as cetuximab, can block tumor growth in&#xD;
      different ways. Some block the ability of tumor cells to grow and spread. Others find tumor&#xD;
      cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses&#xD;
      high energy x- rays to kill tumor cells. Bortezomib and cetuximab may make tumor cells more&#xD;
      sensitive to radiation therapy. Drugs used in chemotherapy, such as cisplatin, work in&#xD;
      different ways to stop the growth of tumor cells, either by killing the cells or by stopping&#xD;
      them from dividing. Giving bortezomib together with cetuximab, radiation therapy, and&#xD;
      cisplatin may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib when&#xD;
      given together with cetuximab and radiation therapy with or without cisplatin in treating&#xD;
      patients with stage IV head and neck cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To evaluate the feasibility and toxicity of bortezomib, cetuximab, and radiotherapy with&#xD;
           or without cisplatin in patients with stage IV squamous cell carcinoma of the head and&#xD;
           neck.&#xD;
&#xD;
        -  To identify the maximum tolerated dose of bortezomib for further clinical phase II&#xD;
           development.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To evaluate the objective response rate, progression-free survival, and overall survival&#xD;
           of patients treated with these regimens.&#xD;
&#xD;
        -  To determine the effects of bortezomib and cetuximab with or without cisplatin on&#xD;
           inhibiting activation of the NF-kB, EGFR, MAPK, and STAT3 signal pathways, expression of&#xD;
           pro-survival and pro-angiogenesis genes regulated by these pathways, and on&#xD;
           proliferation, apoptosis, and angiogenesis.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of bortezomib. Patients are&#xD;
      simultaneously accrued to 1 of 2 treatment groups. Patients are initially accrued to group I&#xD;
      until there are a sufficient number of patients to establish the maximum tolerated dose (MTD)&#xD;
      of bortezomib. Patients are then accrued to group II.&#xD;
&#xD;
        -  Group I: Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43,&#xD;
           and 50. Patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8, 11, 22,&#xD;
           25, 29, 32, 43, 46, 50, and 53. Beginning on day 8 or 9, patients undergo standard&#xD;
           intensity-modulated radiotherapy (IMRT) once daily, 5 days a week, for up to 8 weeks.&#xD;
&#xD;
      Once the MTD of bortezomib is determined, at least 6 and up to 10 additional patients are&#xD;
      accrued and treated at the MTD.&#xD;
&#xD;
        -  Group II: Patients receive cetuximab, bortezomib (beginning at one dose level below the&#xD;
           MTD determined in group I), and IMRT as in group I. Patients also receive cisplatin IV&#xD;
           over 1 hour on days 1, 8, 15, 22, 29, 36, 43, 50, and 57.&#xD;
&#xD;
      Once the MTD of bortezomib is determined, 6 additional patients are accrued and treated at&#xD;
      the MTD.&#xD;
&#xD;
      Patients undergo blood sample collection periodically for correlative laboratory studies.&#xD;
      Samples are analyzed for biomarkers by immunohistochemistry, quantitative reverse&#xD;
      transcriptase-polymerase chain reaction, and ELISA.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically for 2-5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicities and other toxicities as assessed by NCI CTCAE v3.0</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose of bortezomib when administered in combination with cetuximab and radiotherapy with and without cisplatin</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-to-post-treatment changes in biomarkers</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50. Patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8, 11, 22, 25, 29, 32, 43, 46, 50, and 53. Beginning on day 8 or 9, patients undergo standard intensity-modulated radiotherapy (IMRT) once daily, 5 days a week, for up to 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cetuximab, bortezomib (beginning at one dose level below the MTD determined in group I), and IMRT as in group I. Patients also receive cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, 36, 43, 50, and 57.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity-modulated radiation therapy</intervention_name>
    <description>Once daily, 5 days a week, for up to 8 weeks</description>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed squamous cell carcinoma of the head and&#xD;
             neck, including variants or undifferentiated/poorly differentiated carcinoma&#xD;
&#xD;
               -  Previously untreated stage IV disease OR residual disease or regionally recurrent&#xD;
                  disease after prior surgery and/or chemotherapy&#xD;
&#xD;
          -  Must be eligible to receive full-dose radiotherapy and be evaluated and accepted for&#xD;
             treatment by a Radiation Oncologist&#xD;
&#xD;
          -  No clinically measurable distant disease OR has asymptomatic small distant lesions&#xD;
             outside the radiation field ≤ 3 cm in individual or aggregate diameter for which&#xD;
             palliation of local and regional disease is clearly warranted&#xD;
&#xD;
          -  No previously untreated nasopharyngeal cancer (any stage)&#xD;
&#xD;
               -  Recurrent nasopharyngeal carcinoma allowed&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status (PS) 0-1 OR Karnofsky PS 70-100%&#xD;
&#xD;
          -  ANC ≥ 1,500/mcL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mcL&#xD;
&#xD;
          -  Total bilirubin normal (indirect bilirubin ≤ 3 mg/dL in patients with Gilbert's&#xD;
             syndrome)&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine normal OR creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Adequate cognitive and neurologic function&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biologic composition to bortezomib, cetuximab, cisplatin, or other agents used in this&#xD;
             study&#xD;
&#xD;
          -  No peripheral sensory neuropathy ≥ grade 2&#xD;
&#xD;
          -  No concurrent uncontrolled illness including, but not limited to, the following:&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
               -  Psychiatric illness/social situations that would preclude study compliance&#xD;
&#xD;
          -  HIV-negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)&#xD;
&#xD;
          -  More than 3 months since prior cisplatin&#xD;
&#xD;
          -  No prior radiotherapy to the head and neck&#xD;
&#xD;
          -  No prior systemic EGFR inhibitors&#xD;
&#xD;
          -  No prior bortezomib&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No concurrent antiretroviral therapy&#xD;
&#xD;
          -  No concurrent prophylactic filgrastim (G-CSF) or sargramostim (GM-CSF)&#xD;
&#xD;
          -  No concurrent amifostine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carter Van Waes, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Deafness and Other Communication Disorders (NIDCD)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Centers</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>March 1, 2008</study_first_submitted>
  <study_first_submitted_qc>March 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2008</study_first_posted>
  <last_update_submitted>September 29, 2011</last_update_submitted>
  <last_update_submitted_qc>September 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2011</last_update_posted>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

